HLA-C and cancer: CAR-TIL treatment could be used in patients with cancers that are normally not recognized by the immune system, for instance, due to downregulation of MHC or the antigen presentation machinery, lack of suitable neoantigens, or expression of any inhibitory receptors (including but not limited to PD1 and CTLA-4).